PACS Group (PACS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual Meeting scheduled for June 10, 2026, will be held virtually, allowing shareholders to attend and vote online with a 16-digit control number.
Shareholders will vote on director elections, auditor ratification, and executive compensation, with additional business as may arise.
The company emphasizes its mission to revolutionize post-acute care, guided by values of love, accountability, excellence, trust, mutual respect, and commitment.
Voting matters and shareholder proposals
Election of two Class II directors (Evelyn Dilsaver and Mark Hancock) to serve until 2029.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory (non-binding) vote on executive compensation (say-on-pay).
Board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by December 29, 2026.
Board of directors and corporate governance
Board consists of six members divided into three staggered classes; four are independent under NYSE rules.
Messrs. Murray and Hancock have board designation rights and collectively control about 70% of voting power.
The company qualifies as a "controlled company" under NYSE rules and is exempt from certain governance requirements.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent members and written charters.
Lead independent director presides over executive sessions.
Latest events from PACS Group
- Q1 2026 revenue up 11.2%, net income up 184%, and 2026 EBITDA guidance raised to $605–$625M.PACS
Q1 202611 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PACS
Proxy filing28 Apr 2026 - Record 2025 growth, strong financials, and robust M&A pipeline position the company for 2026.PACS
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2025 revenue rose 29% to $5.29B, with strong earnings and robust 2026 growth outlook.PACS
Q4 202527 Feb 2026 - Q2 revenue up 29% year-over-year, but net loss driven by IPO stock compensation expense.PACS
Q2 20241 Feb 2026 - Poised for growth with strong financials, high occupancy, and a focus on quality and innovation.PACS
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Offering 2.78M shares at $39.67 to repay debt; founders retain control; strong growth, high regulatory risk.PACS
Registration Filing29 Nov 2025 - Shareholders will vote on director elections, auditor ratification, and executive compensation matters.PACS
Proxy Filing25 Nov 2025 - Q3 2024 revenue up 29.8% year-over-year, but net income down amid higher costs and compliance issues.PACS
Q3 202420 Nov 2025